Challenges in the management of acute peptic ulcer bleeding

The Lancet

Volumn 381, Issue 9882, 2013, Pages 2033-2043

  Lau, James Y W ^a   Barkun, Alan ^b   Fan, Dai Ming ^c   Kuipers, Ernst J ^d   Yang, Yun Sheng ^e   Chan, Francis K L ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTIHISTAMINIC AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CELECOXIB; CIMETIDINE; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DABIGATRAN; DIPYRIDAMOLE; ERYTHROMYCIN; ESOMEPRAZOLE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LANSOPRAZOLE; LOW MOLECULAR WEIGHT HEPARIN; METOCLOPRAMIDE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; TRANEXAMIC ACID; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; COMPARATIVE STUDY; CORONARY STENT; DRUG ELUTING STENT; EMERGENCY SURGERY; ENDOSCOPY; HEMODYNAMICS; HEMOSTASIS; HOSPITAL ADMISSION; HUMAN; LOW RISK POPULATION; MONOTHERAPY; MORTALITY; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RESUSCITATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STENT THROMBOSIS; THROMBOEMBOLISM; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING;

EID: 84878646830     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60596-6     Document Type: Review

References (88)

1. Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MR, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60: 1327-35.
2. Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion 2011; 84: 102-13.
3. Li Z, Zou D, Ma X, et al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol 2010; 105: 2570-77.
4. Dong WG, Cheng CS, Liu SP, Yu JP. Epidemiology of peptic ulcer disease in Wuhan area of China from 1997 to 2002. World J Gastroenterol 2004; 10: 3377-79.
5. Xinghua L, Zhonglin Y, Honzhi W, et al. Epidemiological survey of peptic ulcer disease in Beijing area: endoscopic analysis of 358644 cases. Chin J Dig 1996; 16: 152-54.
6. Wang JK, Wang RT. Meta-analysis on the epidemiology of Helicobacter pylori infection in China. Zonghua Liu Xing Bing Xue Za Zhi 2003; 24: 443-46.
7. Moran A, Gu D, Zhao D, et al. Future cardiovascular disease in China: markov model and risk factor scenario projections from the coronary heart disease policy model - China. Circ Cardiovasc Qual Outcomes 2010; 3: 243-52.
8. Ho CW, Tse YK, Wu B, Mulder CJ, Chan FK. Use of prophylactic gastroprotective therapy in patients with nonsteroidal anti-inflammatory drug- and aspirin-associated ulcer bleeding: a cross-sectional study. Aliment Pharmacol Ther 2013; published online Feb 21. DOI:10.1111/apt.12259.
9. van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol 2003; 98: 1494-99.
10. Ohmann C, Imhof M, Ruppert C, et al. Time-trends in the epidemiology of peptic ulcer bleeding. Scand J Gastroenterol 2005; 40: 914-20.
11. Sadic J, Borgström A, Manjer J, et al. Bleeding peptic ulcer - time trends in incidence, treatment and mortality in Sweden. Aliment Pharmacol Ther 2009; 30: 392-98.
12. Kang JY, Elders A, Majeed A, et al. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982-2002. Aliment Pharmacol Ther 2006; 24: 65-79.
13. Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104: 1633-41.
14. Laine L, Yang H, Chang SC, Datto C. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001-2009. Am J Gastroenterol 2012; 107: 1190-95.
15. Loperfido S, Baldo V, Piovesana E, et al. Changing trends in acute upper-GI bleeding: a population-based study. Gastrointest Endosc 2009; 70: 212-24.
16. Wu CY, Wu CH, Wu MS, et al. A nationwide population-based cohort study shows reduced hospitalization for peptic ulcer disease associated with H. pylori eradication and proton pump inhibitor use. Clin Gastroenterol Hepatol 2009; 7: 427-31.
17. Rockall T, Logan R, Devlin H, Northfield T. Incidence and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. BMJ 1995; 311: 222-26.
18. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99: 1238-46.
19. Marmo R, Koch M, Cipoletta L, et al. Predictive factors of mortality from nonvariceal upper gastrointestinal hemorrhage: a multicenter study. Am J Gastroenterol 2008; 103: 1639-47.
20. Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalization for peptic ulcer disease in the United States, 1993-2006. Ann Surg 2010; 251: 251-58.
21. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010; 152: 101-13.
22. Hearnshaw SA, Logan RFA, Palmer KR, Card T, Travis SPL, Murphy MF. Outcomes following early red blood transfusion in acute upper gastrointestinal hemorrhage. Aliment Pharmacol Ther 2010; 32: 215-24.
23. ISRCTN Register. Transfusion in Gastrointestinal Bleeding (TRIGGER). http://www.controlled-trials.com/ISRCTN85757829/ (accessed April 9, 2013).
24. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368: 11-21.
25. Jairath V, Brennan CK, Stanworth SJ, et al. Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom. Transfusion 2012; published online Aug 15. DOI:10.1111/j.1537-2995.2012.03849.x.
26. Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol 2007; 102: 290-96.
27. Baradarian R, Ramdhaney S, Chapalamadugu R, et al. Early intensive resuscitation of patients with upper gastrointestinal bleeding decreases mortality. Am J Gastroenterol 2004; 99: 619-22.
28. Srygley FD, Gerardo CJ, Tran T, Fisher DA. Does this patient have a severe upper gastrointestinal bleed? JAMA 2012; 307: 1072-79.
29. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal hemorrhage. Gut 1996; 38: 316-21.
30. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper gastrointestinal hemorrhage. Lancet 2000; 356: 1318-21.
31. Stanley AJ, Dalton HR, Blatchford O, et al. Multicenter comparison of the Glasgow Blatchford and Rockall Scores in the prediction of clinical end-points after upper gastrointestinal hemorrhage. Aliment Pharmacol Ther 2011; 34: 470-75.
32. Saltzman JR, Tabak YP, Hyett BH, Sun X, Travis AC, Johannes RS. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc 2011; 74: 1215-24.
33. Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010; 7: CD005415.
34. Barkun A, Bardou M, Martel M, Gralnek IM, Sung JY. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc 2010; 72: 1138-45.
35. Cook DJ, Guyatt GH, Salena BJ, Laine LA. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterology 1992; 102: 139-48.
36. Spiegel BMR, Vakil NB, Ofman JJ. Endoscopy for acute nonvariceal upper gastrointestinal tract hemorrhage: is sooner better? A systematic review. Arch Intern Med 2001; 161: 1393-404.
37. Lin HJ, Wang K, Perng CL, et al. Early or delayed endoscopy for patients with peptic ulcer bleeding: a prospective randomized study. J Clin Gastroenterol 1996; 22: 267-71.
38. Lee JG, Turnipseed S, Romano PS, et al. Endoscopy-based triage significantly reduces hospitalization rates and costs of treating upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 1999; 50: 755-61.
39. Bjorkman DJ, Zaman A, Fennerty MB, Lieberman D, Disario JA, Guest-Warnick G. Urgent vs. elective endoscopy for acute non-variceal upper-GI bleeding: an effectiveness study. Gastrointest Endosc 2004; 60: 1-8.
40. Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol 2009; 1: 33-47.
41. Bleau BL, Gostout CJ, Sherman KE, et al. Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy. Gastrointest Endosc 2002; 56: 1-6.
42. Jensen DM, Kovacs TO, Jutabha R, et al. Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology 2002; 123: 407-13.
43. Kahi CJ, Jensen DM, Sung JJ, et al. Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Gastroenterology 2005; 129: 855-62.
44. Calvet X, Vergara M, Brullet E, Gisbert JP, Campo R. Addition of a second endoscopic treatment following epinephrine injection improves outcome in high risk bleeding ulcers. Gastroenterology 2004; 126: 441-50.
45. Marmo R, Rotondano G, Piscopo R, et al. Dual therapy versus monotherapy in the endoscopic treatment of high-risk bleeding ulcers: a meta-analysis of controlled trials. Am J Gastroenterol 2007; 102: 279-89.
46. Barkun AN, Martel M, Toubouti Y, Rahme E, Bardou M. Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of meta-analyses. Gastrointest Endosc 2009; 69: 786-99.
47. Sung JJ, Tsoi KK, Lai LH, Wu JC, Lau JY. Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta-analysis. Gut 2007; 56: 1364-73.
48. Marmo R, Rotondano G, Bianco MA, Piscopo R, Prisco A, Cipolletta L. Outcome of endoscopic treatment for peptic ulcer bleeding: is a second look necessary? A meta-analysis. Gastrointest Endosc 2003; 57: 62-67.
49. El Ouali S, Barkun AN, Wyse J, et al. Is routine second look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding? A meta-analysis. Gastrointest Endosc 2012; 76: 283-92.
50. Leontiadis GI, McIntyre L, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006; 1: CD002094.
51. Lanas A, Polo-Tomas M, Garcia-Rodriguez LA, et al. Effect of proton pump inhibitors on the outcomes of peptic ulcer bleeding: comparison of event rates in routine clinical practice and a clinical trial. Scand J Gastroenterol 2013; published online Jan 8. DOI:10.310 9/00365521.2012.758764.
52. Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med 2009; 150: 455-64.
53. Andriulli A, Loperfido S, Focareta R, et al. High-versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicenter, randomized study. Am J Gastroenterol 2008; 103: 3011-18.
54. Wang CH, Ma MH, Chou HC, et al. High-dose vs. non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2010; 170: 751-58.
55. Chan WH, Khin LW, Chung YF, Goh YC, Ong HS. Wong WK. Randomized controlled trial of standard versus high dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding. Br J Surg 2011; 98: 640-64.
56. Liu N, Liu L, Zhang HB, et al. Effect of intravenous proton pump inhibitor regimens and timing of endoscopy on clinical outcomes of peptic ulcer bleeding. J Gastroenterol Heptatol 2012; 27: 1473-79.
57. Hawkey GM, Cole AT, McIntyre AS, Long RG, Hawkey CJ. Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points. Gut 2001; 49: 372-79.
58. Jairath V, Kahan BC, Logan RFA, et al. National Audit of the use of surgery and radiological embolization after failed endoscopic hemostasis for non-variceal upper gastrointestinal bleeding. Br J Surg 2012; 99: 1672-80.
59. Elmunzer BJ, Young SD, Inadomi JM, Schoenfield JP, Laine L. Systematic review of the predictors of recurrent hemorrhage after endoscopic hemostatic therapy for bleeding peptic ulcers. Am J Gastroenterol 2008; 103: 2625-32.
60. Loffroy R, Guiu B. Role of transcatheter arterial embolization for massive bleeding from gastroduodenal ulcers. World J Gastroenterol 2009; 21: 5889-97.
61. Ripoll C, Bañares R, Beceiro I, et al. Comparison of transcatheter arterial embolization and surgery for treatment of bleeding peptic ulcer after endoscopic treatment failure. J Vasc Interv Radiol 2004; 15: 447-50.
62. Eriksson LG, Ljungdahl M, Sundbom M, Nyman R. Transcatheter arterial embolization versus surgery in the treatment of upper gastrointestinal bleeding after therapeutic endoscopy failure. J Vasc Interv Radiol 2008; 19: 1413-18.
63. Larssen L, Moger T, Bjørnbeth BA, Lygren I, Kløw NE. Transcatheter arterial embolization in the management of bleeding duodenal ulcers: a 5·5-year retrospective study of treatment and outcome. Scand J Gastroenterol 2008; 43: 217-22.
64. Venclauskas L, Bratlie SO, Zachrisson K, Maleckas A, Pundzius J, Jönson C. Is transcatheter arterial embolization a safer alternative than surgery when endoscopic therapy fails in bleeding duodenal ulcer? Scand J Gastroenterol 2010; 45: 299-304.
65. Wong TC, Wong KT, Chiu PW, et al. A comparison of angiographic embolization with surgery after failed endoscopic hemostasis to bleeding peptic ulcers. Gastrointest Endosc 2011; 73: 900-08.
66. Ang D, Teo EK, Tan A, et al. A comparison of surgery versus transcatheter angiographic embolization in the treatment of nonvariceal upper gastrointestinal bleeding uncontrolled by endoscopy. Eur J Gastroenterol Hepatol 2012; 24: 929-38.
67. Lau JY, Sung JJ, Lam YH, et al. Endoscopic re-treatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999; 340: 751-56.
68. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled crossover study in healthy subjects. Circulation 2011; 124: 1573-79.
69. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomized crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-24.
70. Sung JJ, Lau J Y, Ching J Y, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152: 1-9.
71. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-30.
72. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745-54.
73. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug eluting stent implantation. JAMA 2007; 297: 159-68.
74. Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 17: 1-8.
75. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation. Chest 2008; 133: 546S-92S.
76. Nikolsky E, Stone G W, Kirtane AJ, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications. J Am Coll Cardiol 2009; 54: 1293-302.
77. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004; 292: 696-703.
78. The Lancet. Managing acute upper gastrointestinal bleeding. Lancet 2011; 377: 1048.
79. Sung JJ, Luo D, Wu JC, et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011; 43: 291-95.
80. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-17.
81. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010; 105: 2533-49.
82. Van Soest EM, Valkhoff VE, Mazzaglia G, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011; 60: 1650-59.
83. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-17.
84. Gisbert JP, Khorrami S, Carballo F, et al. Meta-analysis: Helicobacter pylori eradication therapy vs antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004; 19: 617-29.
85. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin, non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-78.
86. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent bleeding in patients at very high risk: a double blind, randomised trial. Lancet 2007; 369: 1621-26.
87. Wong GLH, Wong VWS, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori negative idiopathic bleeding ulcers. Gastroenterology 2009; 137: 525-31.
88. Gluud LL, Klingenberg SL, Langholz E. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2012; 18: CD006640.